Prelude Therapeutics PRLD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Prelude Therapeutics (PRLD) Business Model and Operations Summary
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Key Insights
Prelude Therapeutics (PRLD) Core Market Data and Business Metrics
Latest Closing Price
$0.7703Market Cap
$41.92 MillionPrice-Earnings Ratio
-0.46Total Outstanding Shares
55.16 Million SharesTotal Employees
131Dividend
No dividendIPO Date
September 25, 2020SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
175 Innovation Boulevard, Wilmington, DE, 19805
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $-120,000 |
| Net Cash Flow From Operating Activities, Continuing | $-102.89 Million |
| Net Cash Flow | $-12.82 Million |
| Net Cash Flow From Investing Activities, Continuing | $90.19 Million |
| Net Cash Flow From Investing Activities | $90.19 Million |
| Net Cash Flow From Operating Activities | $-102.89 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Costs And Expenses | $134.17 Million |
| Benefits Costs and Expenses | $134.17 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Basic Earnings Per Share | $-1.68 |
| Diluted Average Shares | $75.81 Million |
| Net Income/Loss Attributable To Parent | $-127.17 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-127.36 Million |
| Other Comprehensive Income/Loss | $-188,000 |
| Comprehensive Income/Loss | $-127.36 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $7.73 Million |
| Other Non-current Assets | $32.85 Million |
| Assets | $175.51 Million |
| Liabilities And Equity | $175.51 Million |
| Current Liabilities | $25.64 Million |
| Wages | $9.02 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||